Artiva Biotherapeutics (ARTV) Earnings Date, Estimates & Call Transcripts $2.67 +0.20 (+8.10%) Closing price 04:00 PM EasternExtended Trading$2.66 -0.02 (-0.56%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock Artiva Biotherapeutics Earnings Summary Artiva Biotherapeutics issued Q2 2025 earnings on August 6, 2025, reporting an EPS of -$0.87, which missed the consensus estimate of -$0.84 by $0.03. With a trailing EPS of $0.00, Artiva Biotherapeutics' earnings are expected to grow next year, from ($4.95) to ($2.83) per share. Latest Q2 Earnings DateAug. 6EstimatedConsensus EPS (Aug. 6) -$0.84 Actual EPS (Aug. 6) -$0.87 Missed By -$0.03 Q2 2025 Earnings ResourcesQ2 2025 Earnings Report Press Release (8-K) Quarterly Report (10-Q)Powered by Get Artiva Biotherapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Artiva Biotherapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataARTV Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Artiva Biotherapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20252-$0.68-$0.62-$0.65Q2 20252-$0.71-$0.66-$0.69Q3 20252-$0.90-$0.90-$0.90Q4 20252-$0.94-$0.94-$0.94 FY 2025 8 -$3.23 -$3.12 -$3.18 Q1 20261-$0.97-$0.97-$0.97Q2 20261-$0.72-$0.72-$0.72Q3 20261-$0.69-$0.69-$0.69Q4 20261-$0.71-$0.71-$0.71 Artiva Biotherapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025-$0.84-$0.87 -$0.03-$0.87--5/8/2025--$0.68-$0.83 -$0.15-$0.83--11/12/2024--$0.68-$0.92 -$0.24-$0.92$0.30M-8/29/2024Q2 2024-$1.07-$19.10 -$18.03-$16.20-- Artiva Biotherapeutics Earnings - Frequently Asked Questions When did Artiva Biotherapeutics announce their last quarterly earnings? Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earning data on Wednesday, August 6, 2025. Learn more on ARTV's earnings history. Did Artiva Biotherapeutics beat their earnings estimates last quarter? In the previous quarter, Artiva Biotherapeutics (NASDAQ:ARTV) missed the analysts' consensus estimate of ($0.84) by $0.03 with a reported earnings per share (EPS) of ($0.87). Learn more on analysts' earnings estimate vs. ARTV's actual earnings. How much profit does Artiva Biotherapeutics generate each year? Artiva Biotherapeutics (NASDAQ:ARTV) has a recorded net income of -$65.37 million. ARTV has generated $0.00 earnings per share over the last four quarters. What is Artiva Biotherapeutics' EPS forecast for next year? Artiva Biotherapeutics' earnings are expected to grow from ($4.95) per share to ($2.83) per share in the next year. More Earnings Resources from MarketBeat Related Companies scPharmaceuticals Earnings Date Annexon Earnings Date Vor Biopharma Earnings Date ADC Therapeutics Earnings Date Mereo BioPharma Group Earnings Date Aardvark Therapeutics Earnings Date Lifecore Biomedical Earnings Date Inozyme Pharma Earnings Date Heron Therapeutics Earnings Date Sagimet Biosciences Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why BigBear.ai Stock's Dip on Earnings Can Be an Opportunity CrowdStrike Faces Valuation Test Before Key Earnings ReportPost-Earnings, How Does D-Wave Stack Up Against Quantum Rivals?Why SoundHound AI's Earnings Show the Stock Can Move HigherAirbnb Beats Earnings, But the Growth Story Is Losing AltitudeDutch Bros Just Flipped the Script With a Massive Earnings BeatIs Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? This page (NASDAQ:ARTV) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access